IBSA
A spectacular start, on Sunday, April 28 at 1:30 pm for the transoceanic regatta Transat CIC, one of the most demanding tests for solo sailors, who are called to face very tough conditions on their way to New York after over 3,000 miles of navigation, starting from Lorient, Brittany (France).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429033051/en/
Class40 IBSA - The Transat CIC © IBSA | Beppe Raso
The 48 registered skippers – divided into the IMOCA (33, some equipped with foil), Class40 (13) and Vintage (2) categories – positioned themselves along the starting line, in the channel between the Breton coast, before the small town of Lomener, and the island of Groix. After heading South East, on a course designed by the regatta director with the aim of making the start of the transoceanic race spectacular and safe, the skippers began their ascent of the Breton coast.
A conservative start for Alberto Bona on the Class40 IBSA, at his eighth regatta with the Swiss multinational pharmaceutical company. Starting with a lot of sail area, after rigging the gennaker and the solent at the bow, Alberto found himself unable to luff much, remaining for the first stretch in the middle of the fleet, led first by Ambrogio Beccaria (Alla Grande Pirelli), who then left his leading position first to a wild Amélie Grassi (La Boulangère Bio) and then, at the end of the first hour, to Nicolas D’Estais (Café Joyeux), who at the start also had fewer square meters of sail surface at the bow and was very determined to stay ahead of the group.
After about ten miles of navigation, the first tack took the skippers towards the North West, en route to the bay in front of Concarneau; in this phase Alberto gained a good position within the fleet, positioning himself to windward and increasing speed. After leaving the Glénan archipelago – an area very complicated to navigate due to the currents – on the left, the teams manoeuvred again opposite Concarneau, before leaving the influence of the mainland South of Brest and heading for the open sea. After about eight hours of navigation, it was therefore time to say goodbye to the Breton coast and turn the bow in the direction of the South of Ireland, in search of the first low to address, and from which to gain sustained winds – even up to 35 knots – and therefore greater speed.
The wind was found just before dawn today, when the first disturbance brushed the Class40s: finally the boats started running. Bona reached fourth position, less than five miles from the first, a minimum distance that shows how the best navigators in the class have signed up for this regatta, and how the entire race will be played on very small gaps, despite the great distance to cover.
“It will be a balanced and very tough regatta,” had declared Alberto shortly before the start. “The difficulty of sailing at high latitudes has in fact selected the skippers: those taking part in this regatta are very expert, have a perfectly prepared Class40 and are aiming for victory. There are thirteen of us, and at least nine have an equal chance of climbing to the top step of the podium, which makes this regatta both challenging due to the weather conditions and exciting from a sporting perspective. The best a solitary navigator could wish for.”
Giorgio Pisani, Vice President IBSA Group and leader of the project Sailing into the Future. Together, also attended the start of the regatta, on Sunday, April 28: “It’s always a great emotion to see the Class40 IBSA setting sail,” he stated. “Our skipper Alberto Bona has included in the third year of our project the most complex and demanding regatta, as can also be seen from the small number of participants in Class40: the best thirteen. I believe that there are all the conditions for experiencing another wonderful adventure together, one that will require courage and commitment. Arriving in New York is certainly symbolic, the right finish line for the most difficult regatta.”
With a travel time expected between 13 and 15 days from the start, the 13 Class40s will face several lows in the coming days. They will have to navigate in extremely complex conditions, due both to very high waves – which can reach up to six metres – and to very low temperatures. The organisers established no navigation areas, in particular around the Azores islands – to protect cetaceans – and along the Canadian coast, to avoid entering zones with icebergs and where fishing vessels are more numerous. The skippers will therefore have to find the best route to reach the finish line – 130 miles off the coast of New York – as quickly as possible, thus bringing the European ocean sailing under the Statue of Liberty.
THE PROJECT: The three-year project Sailing into the Future. Together was launched in January 2022. The partnership between IBSA and skipper Alberto Bona was born on common bases and values, and aims to use sailing as a corporate communication vehicle towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unites IBSA and Alberto, and the oceanic challenge, in addition to the sporting competition, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards and are part of a path that brings IBSA increasingly closer to the topic of environmental and social sustainability, with a particular focus on inclusive sailing projects for people with disabilities. In November 2022, the Route du Rhum was the first sporting stage of the project Sailing into the Future. Together. In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre. With two victories and three podiums, the record for the highest number of miles covered in 24 hours and over 15,000 miles sailed, Bona won first place overall in the Class40 International Championship. In 2024, between April and July, he will face two of the toughest transatlantic races on the international scene: the Transat CIC from Lorient (France) to New York and the Quebec Saint-Malo (from Canada to France). |
|
THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy aboard Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s former Telecom Italia, he participated in the Transat Jacques Vabre, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the world’s fastest boats, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, in 2020 he finished 7th among the rookies in the first year and 16th overall. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project in partnership with IBSA: after an eighth place in the Route du Rhum 2022, in 2023 Alberto won the Class40 International Championship, closing a season with three podiums and over 15,000 miles covered. |
|
THE BOAT: Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, Alberto Bona’s boat is a Class40 Mach 5 model. Its main characteristics are: scow bow – rounded and with a wider and flatter shape than standard bows – designed to stay high above the water and avoid being submerged; all-round hull, particularly performing in conditions of strong tailwinds; and a large, shielded cockpit, to face extreme conditions of navigation in as comfortable and safe as possible positions. |
|
IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the Company’s 18 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 900 million CHF, and employs over 2,200 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429033051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom